Oncology On The Go
CancerNetwork
All episodes
Best episodes
Seasons
Top 10 Oncology On The Go Episodes
Goodpods has curated a list of the 10 best Oncology On The Go episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Oncology On The Go for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Oncology On The Go episode by adding your comments to the episode page.
S2 Ep17: Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC
Oncology On The Go
01/14/22 • 41 min
In the video series, Bazhenova and Albrecht discussed the following:
· Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC · EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data · Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies · EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions · Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC · Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC · Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC
To watch more videos in CancerNetwork®’s Between the LinesTM series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
S1 Ep38: Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer
Oncology On The Go
12/20/21 • 15 min
The review article focuses on the treatment implications of germline testing and how this type of testing is becoming more commonplace. Gong’s perspective applauds Sokolova and her colleagues for their work and expands on the necessary relationship between medical oncologists and genetic counselors to effectively treat patients with prostate cancer.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
S1 Ep35: Germline Testing in Prostate Cancer: When and Who to Test
Oncology On The Go
11/08/21 • 18 min
Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care models for providing counsel and testing for patients.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
S2 Ep13: First-Line Therapeutic Options in Small Cell Lung Cancer
Oncology On The Go
11/01/21 • 10 min
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
S2 Ep12: OncView™ Podcast: Connie Batlevi, MD, PhD on R/R Follicular Lymphoma Therapy Updates
Oncology On The Go
10/29/21 • 25 min
In the video series, Batlevi discussed the following:
· Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma · Third-Line Therapies in R/R FL · Use of Tazemetostat in R/R FL · Sequencing Changes in R/R FL Therapies
To watch more videos in CancerNetwork®’s OncViewTM series, visit cancernetwork.com/oncview.
S2 Ep11: Between the Lines: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
Oncology On The Go
10/19/21 • 36 min
To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.
S1 Ep31: Inside the Advancing Inclusive Research Site Alliance for Clinical Trial Diversity
Oncology On The Go
09/13/21 • 18 min
Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform the clinicians and researchers to ultimately make clinical trials more accessible and eliminate these disparities.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
08/30/21 • 18 min
These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens.
S2 Ep9: OncView™ Podcast: Updates in Therapies of Relapsed/Refractory Follicular Lymphoma
Oncology On The Go
08/25/21 • 20 min
In the video series, Javier Munoz, MD, MS, FACP, discussed the following:
· Current Treatment Options for Relapsed/Refractory Follicular Lymphoma · Factors in Choosing R/R FL Treatments · Treatment Options for Third-Line R/R FL · Use of Tazemetostat for R/R FL · Changes in Sequencing of R/R FL Therapies
To watch more videos in CancerNetwork®’s OncViewTM series, visit cancernetwork.com/oncview.
09/04/23 • 54 min
Spira, codirector of the Virginia Cancer Specialists Research Institute and director of the Thoracic and Phase I Program, and Das, a clinical associate professor of Medicine and Oncology at Stanford Health, led one part of the discussion regarding the evolution of molecular profiling and next-generation sequencing in the NSCLC space. Moreover, they spoke to clinical and non-clinical factors informing treatment decision-making in the second-line setting. Additionally, they reviewed data from the phase 1 CHRYSALIS trial (NCT02609776) assessing amivantamab as a treatment for patients with disease progression following chemotherapy.
According to data from the CHRYSALIS trial, amivantamab elicited an objective response rate of 40% (95% CI, 29%-51%), and a median duration of response of 11.1 months (95% CI, 6.9-not reached). Additionally, the clinical benefit rate was 74% (95% CI, 63%-83%). Common any-grade adverse effects (AEs) in the study’s safety population that were associated with EGFR inhibition included rash (86%), paronychia (45%), stomatitis (21%), pruritus (17%), and diarrhea (12%).
Sabari, a thoracic medical oncologist at Perlmutter Cancer Center of NYU Langone Health, and Nagasaka, a thoracic oncologist at the University of California, Irvine, also discussed clinical updates in the EGFR exon 20 NSCLC population. They spoke about potential novel treatment options including mobocertinib (Exkivity), as well as potential next steps in research such as moving drugs to earlier lines of treatment and obtaining a better understanding of mechanisms of acquired resistance to treatment.
According to findings from a phase 1/2 trial (NCT02716116), mobocertinib produced an ORR of 28% (95% CI, 20%-37%) by independent-review committee assessment and 35% (95% CI, 26%-45%) per investigator assessment in a cohort of platinum-pretreated patients with EGFR exon 20 insertion mutations. Common AEs reported in the trial included diarrhea and rash.
Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Show more best episodes
Show more best episodes
FAQ
How many episodes does Oncology On The Go have?
Oncology On The Go currently has 158 episodes available.
What topics does Oncology On The Go cover?
The podcast is about Podcasts and Science.
What is the most popular episode on Oncology On The Go?
The episode title 'S1 Ep39: Improving Experience of LGBTQ+ Patients in Cancer Care' is the most popular.
What is the average episode length on Oncology On The Go?
The average episode length on Oncology On The Go is 21 minutes.
How often are episodes of Oncology On The Go released?
Episodes of Oncology On The Go are typically released every 7 days.
When was the first episode of Oncology On The Go?
The first episode of Oncology On The Go was released on Jul 6, 2020.
Show more FAQ
Show more FAQ